TABLE 2

Subgroup Analyses on LOS (Inpatients) and Admission Rate (Outpatients)

SubgroupsLOS, dAdmission rate, %
Trial, nPatients, nEffect Size: MD (95% CI)Subgroup Comparison,aP ValueTrial, nPatients, nEffect Size: RR (95% CI)Subgroup Comparison,aP Value
Virological investigation.02.06
 Available91183−0.74 (−1.32 to −0.16)46200.71 (0.58–0.88)
 Not available67730.01 (−0.17–0.19)33311·04 (0.75–1.44)
Wheeze as diagnostic criteria.42
 Yes111427−0.40 (−0.84–0.04)54780.92 (0.72–1.16)
 No1291−0.03 (−0.80–0.74)00
HS mixed with bronchodilatorb.80.71
 Yes91019−0.42 (−0.89–0.05)54810.76 (0.55–1.06)
 No7937−0.52 (−1.18–0.14)24700.85 (0.52–1.40)
Treatment regimenc.79.07
 A6840−0.52 (−1.14–0.09)43580.93 (0.73–1.20)
 B91116−0.41 (−0.93–0.10)35930.67 (0.52–0.87)
Selection bias.31.13
 Low71151−0.26 (−0.82–0.30)32090.91 (0.68–1.23)
 Unclear/high8805−0.65 (−1.14 to −0.15)47420.68 (0.52–0.87)
  • a Subgroup comparison using χ2 test (degrees of freedom = 1) with P < .1 considered as statistically significant.

  • b One trial had 2 interventions compared with NS: HS mixed with epinephrine and HS alone. We included 2 comparisons, splitting the number of NS group in half for each comparison.

  • c For inpatients: regimen A, every 4 h or 3 initial doses given every 1–2 h followed by every 4–6 h; regimen B, every 6–8 h. For outpatients: regimen A, 1 to 2 doses; regimen B, multiple doses (≥3).